Top

Published in:

01-04-2015 | PHASE II STUDIES

Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma

Authors: Hanna K. Sanoff, Richard Kim, Anastasia Ivanova, Angela Alistar, Autumn J. McRee, Bert H. O’Neil

Published in: Investigational New Drugs | Issue 2/2015

Summary

Purpose: Few treatment options are available for patients with advanced or metastatic hepatocellular carcinoma (HCC). Based on preclinical and early clinical efficacy signals and lack of overlapping toxicity, we undertook this multicenter phase II trial to estimate efficacy and safety of everolimus and pasireotide in advanced HCC. Methods: Patients with advanced HCC not amenable to locoregional therapy and Child-Pugh A cirrhosis received everolimus 7.5 mg PO daily and pasireotide LAR 60 mg IM every 28 days. The primary endpoint was time to progression (TTP), with 26 events needed to evaluate if everolimus + pasireotide improved TTP from 2.8 to 4.4 months, with 80 % power and an alpha of 0.05. Secondary endpoints included response as measured by RECIST modified for HCC, treatment-emergent adverse events, and overall survival. Results: After 24 patients were enrolled, results of a randomized trial showing no benefit of everolimus in HCC were released prompting an unplanned interim analysis that found the conditional probability of rejecting the null hypothesis based on events in those patients was 0.08. Therefore accrual was halted. Patients had a median age of 59 years, 21 (88 %) had BCLC stage C cancer, and 11 (46 %) metastatic disease. Median TTP was 3.5 months (95 % CI 2–5.8) and median survival 6.7 months (95 % CI 6-infinity). Best response was stable disease in ten patients. Grade 3 hyperglycemia occurred in 6 (25 %). There were no grade 4 treatment-emergent events. Conclusion: Despite promising early efficacy signals, we found no benefit for the combination of everolimus and pasireotide in HCC.

Ferlay JIARC (1998) GLOBOCAN 1 cancer incidence and mortality worldwide. IARC Press, Lyon

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390CrossRefPubMed

Dancey J (2010) mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7(4):209–219. doi:10.1038/nrclinonc.2010.21 CrossRefPubMed

Varma S, Khandelwal RL (2007) Effects of rapamycin on cell proliferation and phosphorylation of mTOR and p70(S6K) in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB. Biochim Biophys Acta 1770(1):71–78. doi:10.1016/j.bbagen.2006.07.016 CrossRefPubMed

Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2):128–135. doi:10.1038/nm0202-128 CrossRefPubMed

Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V, Stoupis C, Dufour JF (2007) Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46(5):840–848. doi:10.1016/j.jhep.2006.11.021 CrossRefPubMed

Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, Poon D, Ngo VC, Tran E (2009) RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 13(7):1371–1380. doi:10.1111/j.1582-4934.2008.00364.x CrossRefPubMed

Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135(6):1972–1983. doi:10.1053/j.gastro.2008.08.008, 1983.e1971-1911CrossRefPubMedCentralPubMed

Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, Chang JY, Whang-Peng J, Lin PW, Huang JD, Chen LT (2013) Randomized clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther 37(1):62–73. doi:10.1111/apt.12132 CrossRefPubMed

10.

Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42(3):442–447CrossRefPubMedCentralPubMed

11.

Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC (2002) A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36(3):687–691. doi:10.1053/jhep.2002.35071 CrossRefPubMed

12.

Barbare JC, Bouche O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L (2009) Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer 45(10):1788–1797. doi:10.1016/j.ejca.2009.02.018 CrossRefPubMed

13.

Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E (2007) Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol: WJG 13(23):3164–3170PubMed

14.

Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE, Group HS (2007) Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45(1):9–15. doi:10.1002/hep.21468 CrossRefPubMed

15.

Slijkhuis WA, Stadheim L, Hassoun ZM, Nzeako UC, Kremers WK, Talwalkar JA, Gores GJ (2005) Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol 39(4):333–338CrossRefPubMed

16.

Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V, Australasian Gastro-Intestinal Trials Group Ag HI (2006) Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 95(7):853–861. doi:10.1038/sj.bjc.6603325 CrossRefPubMedCentralPubMed

17.

Shah U, O'Neil B, Allen J, Goldberg RM, Bernard S, Moore D, Venook AP, Morse MM (2009) A phase II study of long-acting octreotide in patients with advanced hepatocellular carcinoma and CLIP score of 3 or higher. Gastrointest Cancer Res: GCR 3(2):45–48PubMedCentralPubMed

18.

Reubi JC, Zimmermann A, Jonas S, Waser B, Neuhaus P, Laderach U, Wiedenmann B (1999) Regulatory peptide receptors in human hepatocellular carcinomas. Gut 45(5):766–774CrossRefPubMedCentralPubMed

19.

Blaker M, Schmitz M, Gocht A, Burghardt S, Schulz M, Broring DC, Pace A, Greten H, De Weerth A (2004) Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 41(1):112–118. doi:10.1016/j.jhep.2004.03.018 CrossRefPubMed

20.

Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A (2004) Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 53(8):1180–1189. doi:10.1136/gut.2003.036053 CrossRefPubMedCentralPubMed

21.

Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60. doi:10.1055/s-0030-1247132 CrossRefPubMed

22.

Zhu AX, Kudo M, Assenat E, Cattan S, Kang Y-K, Lim HY, Poon RTP, Blanc JF, Vogel A, Chen C-L, Dorval E, Peck-Radosavlijevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen L-T (2014) EVOLVE-1: phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. J Clin Oncol 32:2014 (suppl 3; abstr 172)

23.

Bruix J, Gores GJ, Mazzaferro V (2014) Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63(5):844–855. doi:10.1136/gutjnl-2013-306627 CrossRefPubMedCentralPubMed

Title: Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma
Authors: Hanna K. Sanoff
Richard Kim
Anastasia Ivanova
Angela Alistar
Autumn J. McRee
Bert H. O’Neil
Publication date: 01-04-2015
Publisher: Springer US
Published in: Investigational New Drugs / Issue 2/2015
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-015-0209-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 2/2015

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia

Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors

Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement

Keynote webinar | Spotlight on antibody–drug conjugates in cancer